Alligator Bioscience

Declaration of Voting Results & Voting Rights Announcements • Mar 31, 2017

Press release, March 31, 2017

Change in number of shares and votes in Alligator Bioscience AB (publ)

Lund, Sweden - Alligator Bioscience AB (Nasdaq Stockholm; ATORX) announced today that the number of shares and votes in Alligator Bioscience AB (publ) has increased due to that 575,000 warrants in the warrant program 2014/2017 issued pursuant to the resolution by the extraordinary shareholders' meeting on 5 November 2013 have been excercised for subscription of 575,000 new shares. As of March 31, 2017, the number of shares and votes in Alligator Bioscience AB amounts to 71,388,615.

About Alligator

Alligator is a biotechnology company that develops innovative immune activating antibody drugs for tumor-directed immunotherapy. The Company has a pipeline of lead clinical and preclinical product candidates: ADC-1013, ATOR-1015 and ATOR-1016 as well as various research candidates. In August 2015, ADC-1013 was out-licensed to Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for further development and commercialization. The Company's shares are listed on Nasdaq Stockholm under the ticker "ATORX". The Company is headquartered in Lund, Sweden, and has approximately 40 employees.

For more information, please visit www.alligatorbioscience.com.

For further information, please contact:

Per Norlén, CEO Telephone: + 46 46 286 42 80 (switchboard) E-mail: per.norlen@alligatorbioscience.com

Rein Piir, VP Investor Relations Telephone: +46 708 53 72 92 E-mail: rein.piir@alligatorbioscience.com

Per-Olof Schrewelius, CFO Telephone: +46 46 286 42 85 E-mail: per-olof.schrewelius@alligatorbioscience.com

The information in the press release is such that Alligator Bioscience AB is required to disclose pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08.30 CET on March 31, 2017.